Anticancer drug discovery
Professor Barry Potter, Supernumerary Fellow in Pharmacology, lectured on his anticancer drug discovery work as a Keynote Speaker at the 2019 Research Meeting of the Lister Institute for Preventive Medicine in Oxford and was an Invited Speaker at the 63rd German Congress of Endocrinology of the Deutsche Gesellschaft für Endokrinologie, in Giessen, Germany.
Professor Potter was also chosen as one of the honorary graduands of the University of Bath for the academic year 2019-2020 to be awarded the degree of Doctor of Science honoris causa. The citation read “in recognition of his distinguished career and extensive experience in Education and Science and world-class academic contributions to Biology, Medicinal Chemistry and Chemical Biology.”
As an entrepreneur, he co-founded the University of Bath—Imperial College London spin-off company Sterix Ltd., built around his seminal work in the field of steroid sulfatase inhibitors, which includes the design of the anti-breast cancer drug Irosustat. He has published over 500 papers and is listed as co-inventor on more than 700 patent applications, over 400 of which have been granted to date. Several of his discoveries form the basis of tools (some of them now part of commercial kits) widely used in pharmacology and chemical biology.
Professor Potter provides mentorship to College graduate students in Chemistry, supervises research students and postdoctoral research associates, gives ad hoc lectures and teaches and examines in Biomedical Sciences and on the MSc Pharmacology course.
Published: 30 September 2020